THE PURPOSE FOR THIS MODIFICATION IS TO DE-OBLIGATE EXCESS FY24 FUNDS, IN ORDER TO REFLECT ACTUAL AMOUNTS U…
Award details are derived from public USAspending.gov records. Not a bid recommendation.
Award details
- Award ID
- W81K0021P0235
- Contractor
- BIOMERIEUX INC
- Awarding agency
- Department of Defense
- Sub-agency / office
- Department of the Army
- Award amount
- $1,577,741
- Period of performance
- Oct 1, 2021 – Sep 30, 2025
- NAICS
- 325413 — In-Vitro Diagnostic Substance Manufacturing
- Place of performance
- DURHAM, NC, 277011444, USA
- Competition
- COMPETED UNDER SAP · Set-aside: NO SET ASIDE USED. · 2 offers
- Pricing
- FIRM FIXED PRICE
- Financial breakdown
- Current value $1,577,741 · Obligated $1,459,984 · Potential value $1,577,741 · Latest action obligation $-55,256 · Outlays $56,458
Public award description
THE PURPOSE FOR THIS MODIFICATION IS TO DE-OBLIGATE EXCESS FY24 FUNDS, IN ORDER TO REFLECT ACTUAL AMOUNTS USED DURING PERFORMANCE OF THE CONTRACT IN FY24 (01 OCTOBER 2023 - 30 SEPTEMBER 2024.
Find out who's winning similar federal contracts
Discover comparable awards, related contractors, and agency purchasing history.
Related intelligence
- Agency: Department of Defense
- PSC 6515 — Medical and Surgical Instruments, Equipment, and Supplies
- Federal market intelligence software